In October 2023, Premier Research announced the appointment of Elaina NMs. Haeuber is the Senior Vice President of Oncology at the Company. At present, female leaders can be seen in all professional teams in the field of Pumir Medicine.
Ms. Haeuber holds a bachelor's degree from Boston University and a master's degree from the University of Illinois at Chicago. She has more than 20 years of project management and leadership experience in the biotech, pharmaceutical and CRO industries.
Commenting on Ms. Haeuber's appointment, Dr. Michael Arlotto, Chief Operating Officer of Promir Therapeutics, said, "Promere Therapeutics will continue to expand and strengthen its oncology team as the number of clinical research pipelines continues to grow due to the increasing depth and complexity of oncology research. Ms. Haeuber has extensive experience in biotechnology and CRO in two key aspects of drug development. She has overseen and executed full-process research projects in oncology across multiple indications, cells and genes**, as well as all phases of immunological and targeted** research. She will be the outstanding leader of Promir's oncology team and will provide sponsors with more specialized insights to help them bring cutting-edge** to market.
According to the Global Cancer Observatory, there were about 19.3 million new cancer cases and 10 million cancer deaths worldwide in 2020. The global cancer burden is expected to continue to increase through 2040, with about 28.4 million cancer cases, up 47% from 2020.
Faced with the huge demand for cancer diagnosis and treatment, Promir Biopharma actively participates in research and development. Over the past 5 years, Promir has supported or participated in the management of 194 hematology and oncology programs, including 47 rare oncology and hematology programs, and 36 cell- and gene-based** oncology and hematology trials.
"I am honored to join Promir's oncology team to provide additional support and expertise to the industry's cutting-edge oncology research," said Ms. Haeuber, the new leader of Promir's oncology team. I hope to contribute to improving the current state of healthcare, so that more patients can get what they need." What I am facing is not only a job, but also a great mission. I look forward to working with the team at Pumir Pharma to contribute more to the development of the medical field." ”
About Pumir Pharmaceuticals:
Premier Research has a comprehensive understanding of oncology and hematology, rare diseases, neuroscience, and global development and registration strategies. With more than 30 years of experience in product development, the company can provide a one-stop full range of services from initial strategy development, clinical development to final regulatory filing. For more information, please search WeChat***Premier Research to follow and inquire.